SCHEDULE: Pelthos Secures $9M Convertible Note from Ligand

Pelthos Therapeutics Inc. has secured a $9.0 million Senior Secured Convertible Note from Ligand Pharmaceuticals Incorporated, enhancing its financial position and granting Ligand significant royalty interests.

Summary

• Ligand Pharmaceuticals Incorporated acquired a $9.0 million Senior Secured Convertible Note from Pelthos Therapeutics Inc. on November 6, 2025, funded by Ligand's general working capital.
• The note matures in 24 months, bears an 8.5% annual interest rate (payable quarterly in cash or capitalized), and ranks senior to most other indebtedness.
• The initial conversion price is $34.442 per share, subject to reduction to $29.73 under certain conditions and shareholder approval, or to a 5-day VWAP at maturity if cash payments are restricted.
• As consideration, Ligand receives a 2.5% royalty on net sales of XepiTM and a pro rata share of royalty and milestone payments from Sato Pharmaceutical Co., Ltd. for ZELSUVMITM.
• Ligand's beneficial ownership of Pelthos common stock is capped at 49.9% upon conversion of the note or Series A Preferred Stock.
• The Convertible Notes are secured by a lien on XepiTM revenue and Sato payments for ZELSUVMITM.
• Ligand's lock-up agreement was amended, immediately releasing 25% of its subject shares from restrictions, with the remaining shares locked until December 31, 2025.

Sentiment

Score: 7

Explanation: The filing indicates a successful capital raise for Pelthos Therapeutics, providing $9.0 million in funding. While the terms include royalty concessions and potential dilution, securing financing is generally positive for a biotech company. For Ligand, it represents a strategic investment with a secured position and royalty upside, balanced by a beneficial ownership cap.

Positives

• Pelthos secured $9.0 million in financing, improving its liquidity and capital structure.
• The Convertible Note ranks senior to most other indebtedness, providing a level of security for the investor.
• The financing includes royalty streams from XepiTM and ZELSUVMITM, diversifying the return for investors.
• Ligand's lock-up agreement was amended, immediately releasing 25% of its shares, potentially increasing trading liquidity for Ligand.

Negatives

• The Convertible Note bears an 8.5% annual interest rate, which is a cost to Pelthos.
• Pelthos granted significant royalty interests (2.5% of XepiTM net sales for Ligand, plus ZELSUVMITM payments) as part of the financing, which will reduce future revenue streams.
• The conversion price can be reduced to $29.73, potentially leading to greater dilution for existing shareholders if the stock price is higher.
• The notes are secured by key product revenues (XepiTM and ZELSUVMITM payments), potentially limiting Pelthos's financial flexibility.

Risks

• Dilution Risk: The conversion of the Convertible Notes into common stock could dilute the ownership of existing shareholders, especially if the conversion price adjusts downwards.
• Shareholder Approval Risk: The reduction of the conversion price below $34.442 per share requires shareholder approval, which may not be obtained, affecting the terms for investors.
• Operational Risk: Pelthos's ability to make cash payments on the Convertible Notes depends on its financial performance and the terms of Permitted Senior Indebtedness, potentially leading to automatic conversion price adjustments if payments cannot be made.
• Liquidity Risk: The lock-up agreement on Ligand's shares, though partially released, still restricts a significant portion of its holdings until December 31, 2025, potentially impacting market liquidity for those shares.

Future Outlook

Pelthos Therapeutics Inc. has committed to seeking shareholder approval for the potential reduction of the Convertible Note's conversion price and will file a resale registration statement for certain common stock shares held by investors within 60 days of the financing closing.

Industry Context

This filing reflects a common financing strategy in the biotechnology and pharmaceutical sectors where established players like Ligand Pharmaceuticals provide capital to smaller therapeutic companies like Pelthos Therapeutics Inc. in exchange for convertible debt and royalty interests. This structure allows Pelthos to fund its operations and development, while Ligand gains exposure to potential product success (XepiTM, ZELSUVMITM) with downside protection through a secured note and a cap on equity ownership to avoid triggering certain regulatory or governance thresholds.

Comparison to Industry Standards

• The 8.5% interest rate on the secured convertible note is within a reasonable range for growth-stage biotech companies, reflecting both the risk profile and the secured nature of the debt.
• The royalty structure (2.5% on XepiTM and a share of ZELSUVMITM payments) is a standard mechanism in biotech financing, allowing investors to participate directly in product success without full equity dilution upfront. For example, similar royalty deals have been seen with companies like Royalty Pharma, which specializes in acquiring royalty interests in approved and late-stage pharmaceutical products.
• The 49.9% beneficial ownership cap is a common strategy for investors to maintain significant influence and economic interest without becoming a majority owner, which could trigger different accounting treatments or regulatory requirements.
• The inclusion of a conversion price adjustment mechanism (e.g., to $29.73 or VWAP at maturity) is a protective measure for investors, common in convertible debt structures, to account for future stock performance or financial constraints of the issuer.

Corporate Governance

Stakeholder Impact

• Shareholders (Pelthos): Potential for dilution if the Convertible Note is converted, especially if the conversion price adjusts downwards. However, the financing provides capital for company operations, which could benefit long-term value. The 49.9% voting cap on Ligand limits its direct control.
• Ligand Pharmaceuticals (Investor): Gains a secured investment with an 8.5% interest rate, royalty streams from key products (XepiTM, ZELSUVMITM), and potential equity upside, while maintaining a strategic ownership stake below majority control. 25% of its previously locked-up shares are now free to trade.
• Creditors (Pelthos): The new Convertible Note ranks senior to most other indebtedness, potentially impacting the recovery prospects of junior creditors in a default scenario.
• Employees/Customers/Suppliers (Pelthos): The financing provides capital to support ongoing operations and product development, which could ensure job stability, continued product supply, and payment to suppliers.

Next Steps

• Pelthos Therapeutics Inc. will seek shareholder approval for the potential reduction of the Convertible Note's conversion price.
• Pelthos Therapeutics Inc. will prepare and file a resale registration statement with the SEC on or prior to the 60th day following the closing of the Convertible Note Financing (approx. January 5, 2026).
• Pelthos Therapeutics Inc. will use reasonable best efforts to cause the registration statement to be declared effective by the SEC by the earlier of the 90th calendar day after closing (approx. February 3, 2026) or 2nd business day after SEC notification of no review.
• Ligand's remaining locked-up shares will be released from restrictions after December 31, 2025.

Key Dates

Recommendation

The filing details a financing event that provides Pelthos Therapeutics with $9.0 million in capital, which is generally positive for a development-stage biotech company. However, the terms include significant royalty concessions and potential future dilution from the convertible note. For Ligand, it's a strategic investment with a secured position and royalty upside, but the 49.9% ownership cap limits its direct control. The immediate release of 25% of Ligand's locked-up shares could introduce some selling pressure. Given the mixed implications of the financing terms (capital infusion vs. dilution/royalty burden) and the strategic nature of Ligand's investment, a "hold" recommendation is appropriate as investors assess the long-term impact of the capital raise on Pelthos's financial health and product development, and how the market absorbs the potential for future share conversions.

Keywords

Pelthos Therapeutics, Ligand Pharmaceuticals, Convertible Note, SEC Filing, Schedule 13D/A, Biotechnology, Pharmaceuticals, Financing, Equity Investment, Royalty Agreement, Xepi, ZELSUVMI, Shareholder Approval, Lock-Up Agreement